Hematologic Oncology Update

Featuring an interview with Dr L Elizabeth Budde, including the following topics:
Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)
Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)
Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study (17:30)
Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and polatuzumab vedotin in the second-line setting (23:18)
Case: A woman in her early 70s with R/R DLBCL receives glofitamab monotherapy in the third-line setting (32:52)
Case: A man in his early 80s with R/R DLBCL experiences disease progression after lisocabtagene maraleucel therapy, which was bridged with epcoritamab and gemcitabine/oxaliplatin (37:35)

CME information and select publications

Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:
Introduction (0:00)
First-Line Treatment (1:33)
Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36)

CME information and select publications

Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:
Introduction (0:00)
First-Line Therapy (2:48)
Relapsed/Refractory Disease (39:30)

CME information and select publications

Featuring perspectives from Dr Brad S Kahl, Dr Jeff Sharman and Dr Tanya Siddiqi, including the following topics:
Introduction (0:00)
Trials in Progress (1:12)
Chronic Lymphocytic Leukemia (7:09)
Diffuse Large B-Cell Lymphoma (32:35)
Mantle Cell Lymphoma (58:25)
Follicular Lymphoma (1:14:49)

CME information and select publications

Featuring an interview with Dr Douglas W Sborov, including the following topics:
DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00)
Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26)
Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36)
Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48)
Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00)
Prevention and management of ophthalmic events related to treatment with belamaf (21:27)
Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49)
Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27)
Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53)

CME information and select publications